XERS · Xeris Biopharma Holdings, Inc.
AI read · Neutral
The AI's read
The filing gives no reason for the sale and no update about Xeris Biopharma's business. A reported sale alone does not show that the company's prospects have changed.
An insider at Xeris Biopharma sold $312,215 worth of shares, according to a recent SEC report.
Neutral
Xeris Biopharma reported an insider sale worth $312,215. The filing gives no reason or business update, so it does not change the company's outlook.
Get alerts for XERS
Follow Xeris Biopharma Holdings, Inc. (XERS) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for XERSFree on the App Store and Google Play, or on the web.